Bisceglia Irma, Canale Maria Laura, Silvestris Nicola, Gallucci Giuseppina, Camerini Andrea, Inno Alessandro, Camilli Massimiliano, Turazza Fabio Maria, Russo Giulia, Paccone Andrea, Mistrulli Raffaella, De Luca Leonardo, Di Fusco Stefania Angela, Tarantini Luigi, Lucà Fabiana, Oliva Stefano, Moreo Antonella, Maurea Nicola, Quagliariello Vincenzo, Ricciardi Giuseppina Rosaria, Lestuzzi Chiara, Fiscella Damiana, Parrini Iris, Racanelli Vito, Russo Antonio, Incorvaia Lorena, Calabrò Fabio, Curigliano Giuseppe, Cinieri Saverio, Gulizia Michele Massimo, Gabrielli Domenico, Oliva Fabrizio, Colivicchi Furio
Integrated Cardiology Services, Cardio-Thoracic-Vascular Department, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Division of Cardiology, Ospedale Versilia, Azienda Usl Toscana Nord Ovest, Lido di Camaiore, Italy.
Front Cardiovasc Med. 2023 Sep 15;10:1223660. doi: 10.3389/fcvm.2023.1223660. eCollection 2023.
In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer survivors (CS) has grown considerably and includes: (1) Patients cured and free from cancer who may be at risk of late-onset cancer therapy-related cardiovascular toxicity (CTR-CVT); (2) Patients with long-term control of not-curable cancers in whom CTR-CVT may need to be addressed. This paper highlights the importance of the cancer care continuum, of a patient-centered approach and of a prevention-oriented policy. The ultimate goal is a personalized care of CS, achievable only through a multidisciplinary-guided survivorship care plan, one that replaces the fragmented management of current healthcare systems. Collaboration between oncologists and cardiologists is the pillar of a framework in which primary care providers and other specialists must be engaged and in which familial, social and environmental factors are also taken into account.
在癌症领域,从初次诊断之时起直至生命终结,患者都被视为幸存者。随着早期诊断和治疗水平的提高,癌症幸存者(CS)的数量大幅增长,其中包括:(1)已治愈且无癌症的患者,他们可能面临与癌症治疗相关的迟发性心血管毒性(CTR-CVT)风险;(2)对无法治愈的癌症实现长期控制的患者,这类患者可能需要应对CTR-CVT问题。本文强调了癌症照护连续体、以患者为中心的方法以及预防导向政策的重要性。最终目标是对癌症幸存者进行个性化照护,而这只有通过多学科指导的生存照护计划才能实现,该计划可取代当前医疗系统的分散管理。肿瘤学家和心脏病学家之间的合作是一个框架的支柱,在这个框架中,初级保健提供者和其他专科医生必须参与其中,同时还要考虑家庭、社会和环境因素。